N@N

BioSphere Medical Schedules Fourth Quarter 2008 Financial Results Conference Call February 12

  //health-fitness.news-articles.net/content/2009/ .. nancial-results-conference-call-february-12.html
  Published in Health and Fitness on Thursday, January 29th 2009 at 10:25 GMT, Last Modified on 2009-01-29 10:26:04 by Market Wire

ROCKLAND, Mass.--([ BUSINESS WIRE ])--BioSphere Medical, Inc. (NASDAQ: BSMD), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors, and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy, today announced that it plans to issue its financial results for the fourth quarter ended December 31, 2008 on February 11 after the close of the stock market. Management will conduct a conference call on Thursday, February 12 at 8:30 a.m. Eastern Time to discuss these results.

The number to dial is 1-888-563-6275 (US/Canada) or 706-643-3137 (International), and the conference ID is 80124190. Please call in approximately ten minutes before the call is scheduled to begin. The live web cast will be available at the "Investors" section of BioSphere's web site at [ www.biospheremed.com ]. A replay of the web cast will also be available at BioSphere's web site.

About BioSphere Medical, Inc.

BioSphere Medical, Inc., a medical device company based in Rockland, Massachusetts, seeks to develop and commercialize products used in minimally invasive diagnostic and therapeutic applications based upon its pioneering proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties that are designed for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure, as well as in a number of other new and established medical treatments.